News archive search
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
Active search
MarketBeat Market update
Search results
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
This page provides financial information for TriSalus Life Sciences, Inc. (NASDAQ: TLSIW), focusing on its price-to-earnings forward ratio. The content indicates that the market was closed with no trades at the time of viewing, and includes copyright information from FactSet, American Bankers Association, and …
TriSalus Life Sciences (NASDAQ:TLSI) announced its quarterly earnings, reporting a loss of $0.16 per share, which met analyst expectations, while revenue exceeded estimates at $11.41 million. The company's gross margin improved to 86.8%, and management reiterated its 2026 revenue guidance of $54 million to …
TriSalus Life Sciences (NASDAQ: TLSI) reported second-quarter EPS that missed analyst estimates by $0.01, coming in at $-0.160. However, the company's revenue for the quarter exceeded expectations, reaching $11.41 million against a consensus estimate of $10.79 million. Despite the EPS miss, TriSalus Life Sciences' …
TriSalus Life Sciences Inc (TLSI) announced a new CMS G-code for TriNav reimbursement in office-based labs, significantly expanding market access and supporting full-year 2026 revenue guidance of $54 million to $57 million. While gross margin improved to 86.8%, Q2 revenue growth was modest at …
TriSalus Life Sciences reported Q2 revenue of $11.4 million, surpassing forecasts, driven by increased adoption of its TriNav system. Despite the revenue beat, the stock slipped after hours due to a wider adjusted EBITDA loss and higher sales and marketing expenses. The company reiterated …
TriSalus Life Sciences, Inc. (TLSI) reported its 2026 quarterly results, showing revenue of $11.41M, which was nearly flat year-over-year, and a net loss of ($9.19M), resulting in a diluted loss per share of ($0.16). The company highlighted stable revenue, improved gross margin, continued commercial …
This article provides a discussion forum for TriSalus Life Sciences (TLSI) stock. It encourages investors to share insights, analysis, news, and opinions to foster a community around the company's financial performance and future prospects. The forum aims to be a resource for informed decision-making …
The article focuses on the "Price to earnings forward" metric for TriSalus Life Sciences, Inc. (BOATS:TLSIW), a company listed on the Blue Ocean Alternative Trade System. It appears to be a financial data page from TradingView, providing an overview of the company's financials without …
TriSalus Life Sciences Inc (TLSI) has a financial score of 6.94, ranking 177th out of 384 in the Biotechnology & Medical Research industry, indicating stable financial status and high operating efficiency. The company's latest quarterly revenue was $8.90M, a 2.92% year-over-year decrease, with net …
TriSalus Life Sciences announced that its CEO and CFO will participate in the Canaccord Genuity 46th Annual Growth Conference, including one-on-one meetings and a fireside chat. The company focuses on oncology, integrating novel drug delivery technology with standard-of-care therapies for solid tumors, utilizing its …
TriSalus Life Sciences announced that its CEO and President, Mary Szela, and CFO, David Patience, will participate in the Canaccord Genuity 46th Annual Growth Conference. They will engage in one-on-one meetings on August 11-12 and a fireside chat on August 12 at 8:30 a.m. …
This article provides a technical analysis of TriSalus Life Sciences Inc (TLSI), focusing on its price momentum, support and resistance levels, and various technical indicators. It details the stock's current momentum score within the Biotechnology & Medical Research industry and offers insights from indicators …
This article provides a comprehensive overview of TriSalus Life Sciences Inc.'s (TLSI) cash flow statements, including operating, investing, and financing activities, spanning multiple quarters and years. It details various financial metrics such as net income, capital expenditures, and free cash flow, along with year-over-year …
TriSalus Life Sciences Inc. (TLSI) is an oncology-focused medical technology company with a stock price of $4.22, down 1.17%. The company exhibits high growth potential and healthy fundamentals, with analysts largely rating it as a "Buy" with a target price of $9.00. Its platform …
This article provides a revenue breakdown for TriSalus Life Sciences, Inc. (NASDAQ: TLSI). Last year, the company generated $45.15 million USD, with its top-performing segment, Innovative Drug Delivery Technology and Immune-oncology Therapeutic, contributing the entirety of this amount. The United States was the sole …
TriSalus Life Sciences has commenced patient enrollment for the PREDICTT clinical trial, evaluating its Pressure-Enabled Drug Delivery (PEDD) approach for liver tumors. The study, conducted at The University of Texas MD Anderson Cancer Center, aims to optimize the delivery of Y90 radioembolization therapy using …
TRISALUS LIFE SCIENCES recently disclosed $90,000 in lobbying expenditures for Q2 2026, focusing on "Medicare and Medicaid reimbursement issues." This update also details significant insider trading activity for TLSI stock, with 26 transactions in the past 6 months showing more sales than purchases, and …
TriSalus Life Sciences, Inc. (Nasdaq: TLSI) will host a conference call and webcast on Thursday, August 6, 2026, at 4:30 PM Eastern Time to discuss its financial results for the quarter ended June 30, 2026. The company, an oncology firm, aims to transform solid …
TriSalus Life Sciences will host a conference call and webcast on August 6, 2026, at 4:30 PM Eastern Time to discuss its financial results for the quarter ended June 30, 2026. A press release detailing the results will be issued prior to the call. …
Search by ticker symbol or company name and select a result to open its chart.